V gamma 9 V delta 2 T cell receptor (Vγ9Vδ2 TCR)

The V gamma 9 V delta 2 T cell receptor (Vγ9Vδ2 TCR) is the defining feature of the most prominent gamma delta T cell subset in human peripheral blood, accounting for approximately 1-5% of total T cells [1]. Unlike conventional alpha-beta T cells, the Vγ9Vδ2 TCR recognizes non-peptide phosphoantigens (PAs) in an MHC-independent manner [2]. This recognition process is unique and requires the presence of butyrophilin proteins, specifically BTN3A1 and BTN2A1, which act as sensors for intracellular PA levels [3]. These receptors play a critical role in the early immune response to pathogens and the surveillance of transformed cells, which often accumulate endogenous PAs like isopentenyl pyrophosphate (IPP) due to metabolic dysregulation [4]. In therapeutic contexts, the Vγ9Vδ2 TCR is targeted to harness the potent cytotoxic and pro-inflammatory capabilities of these cells against malignancies [5]. Current pharmacological approaches include the use of aminobisphosphonates to indirectly trigger the receptor by increasing intracellular IPP levels [6]. Additionally, novel bispecific antibodies and monoclonal antibodies are being developed to directly engage the TCR or its mandatory co-receptors to induce tumor-specific lysis [7]. These therapies aim to overcome the limitations of traditional T-cell therapies by utilizing the MHC-independent nature of Vγ9Vδ2 T cells, which reduces the risk of graft-versus-host disease [8]. Citations: [1] PubMed: 23024254; [2] Nature Reviews Immunology: 13(2); [3] Science: 367(6481); [4] Nature Reviews Cancer: 12(3); [5] Frontiers in Immunology: 11; [6] Blood: 105(12); [7] Journal for ImmunoTherapy of Cancer: 9(6); [8] Cancer Discovery: 10(11).

Other names

Vgamma9Vdelta2 TCRVg9Vd2 TCRVγ9Vδ2 T-cell receptorGamma-delta T-cell receptor subsetGDTCR

Indirect activation via phosphoantigen accumulation, direct agonism via butyrophilin modulation, and bispecific T-cell engagement.